In-Situ Cryo-Immune Engineering of Tumor Microenvironment with Cold-Responsive Nanotechnology for Cancer Immunotherapy

After the in-situ cryo-immune engineering treatment, the ratio of the CD8+ cytotoxic T cells to the immunosuppressive regulatory T cells was increased by more than 100 times, in not only the primary tumors with cryosurgery, but also distant tumors without freezing.